Press Release

  View printer-friendly version

« Back

West Celebrates Official Opening of New Global Manufacturing Facility in Waterford, Ireland and the launch of Westar® Select Component Offering

EXTON, Pa., July 19, 2018 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the official opening of its new Waterford, Ireland facility, a global center of excellence for West's advanced manufacturing network, and the launch of a new product line—Westar® Select. Customers and senior-level Irish government officials joined West at a ribbon-cutting ceremony to celebrate the facility's opening and to recognize West's ongoing commitment to improving patient lives through their products and services.

(PRNewsfoto/West Pharmaceutical Services, I)

"West is very pleased to celebrate the official opening of our state-of-the-art facility in Waterford, as well as the launch of Westar Select, both of which are the culmination of efforts by many to support our company's commitment to meeting the dynamic needs of our pharmaceutical and biotech partners," said Eric Green, President and CEO, West. "Our investment in Waterford, in addition to our previously announced investments in Kinston, N.C., Jurong, Singapore, and Dublin, Ireland, enable West to provide the highest levels of quality across the products and services we provide for the global customer base we serve."

The new, 20,500 square meter facility, situated on a 44-acre campus, will produce West's proprietary elastomeric laminate sheeting, which is used to package insulin for use in pen injectors. Additionally, it will offer high-value finishing for components, including stoppers and plungers, produced at other West facilities around the world. These services, designed to mitigate the risk of potential contamination and compatibility issues with packaging components, include pharmaceutical washing (Westar® RS components), Envision® verification, steam sterilization (Westar® RU components), and flexible packaging offerings.

The Waterford site will also be among the first in West's global manufacturing network to produce Westar Select, the latest in West's Westar® quality enhancement offering. In addition to a tighter particulate specification, Westar Select will be made available through an optimized global manufacturing network with multi-site production capabilities to ensure a continuous supply chain, while helping to reduce regulatory complexity for customers.

"At West, we understand that our customers are increasingly challenged to meet new and expanding regulatory requirements, and with that comes an expectation for the highest quality in drug delivery and packaging components," said David Montecalvo, Senior Vice President, Global Operations and Supply Chain, West.  "Westar Select employs next generation manufacturing capabilities and product attributes that enable us to optimize product specifications, and to respond more rapidly and flexibly to customer demand and evolving market needs."

West's Waterford facility currently employs approximately 100 people in both local and global functions, with plans for additional hiring. Commercial production in Waterford is expected this year. West also has a manufacturing and development center in Dublin that provides design, development and manufacturing services for pharmaceutical and medical technology customers. The Dublin site recently completed an expansion to accommodate new customer programs and employs approximately 600 people.

For more information on West and current job openings in the region, please visit

Forward-Looking Statements
Certain forward-looking statements are included in this release. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. Examples of these forward-looking statements include (but are not limited to) West's statements with respect to planned manufacturing capabilities and job creation, and statements regarding West's Westar Select product line and similar words and phrases. While forward-looking statements reflect West's good faith beliefs, assumptions and expectations, they are not guarantees of future performance. There is no certainty that the investments made by West in its global manufacturing footprint or West's Westar Select product line, or any other West products, will achieve any level of commercial success. These forward-looking statements involve a number of risks and uncertainties. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2017. Except as required by law or regulation, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world's pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West's 2017 net sales of $1.6 billion reflect the daily use of approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

West and the diamond logo, By your side for a healthier world™, Westar® and Envision® are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions.


Investor Contact:                                             

Media Contact:

Quintin Lai                                                                        

Michele Pelkowski

Vice President, Investor Relations                        

Senior Director, Global Communications




Cision View original content with multimedia:

SOURCE West Pharmaceutical Services, Inc.